Table 3.

Correlation of PD-L1 mRNA levels at baseline with clinical status of patients and laboratory parameters.

		PD-L1 mRNA FA (Median, %)	p-Value
Age	<60.5 vs. ≥60.5	0.00125 vs. 0.00243	0.83
Gender	Male vs. Female	0 vs. 0.00272	0.43
Stage	III vs. IV	0.00505 vs. 0.00347	0.06
ECOG PS	0 vs. 1	0.00257 vs. 0.0011	0.44
Primary tumor location	Body-tail vs. Head	0 vs. 0.00367	0.14
Baseline CA 19-9	≤median 266.6 vs. >median 266.6	0.00359 vs. 0	0.29
Baseline NLR	≤median 2.21 vs. >median 2.21	0.0031 vs. 0.000693	0.39
Baseline PLR	≤median 128.99 vs. >median 128.99	0.00173 vs. 0.00243	0.44
Number of metastatic sites	1–2 vs. 3–5	0.000973 vs. 0.003	0.43
Liver metastases	Yes vs. No	0.000693 vs. 0.00287	0.38
Lung metastases	Yes vs. No	0 vs. 0.00173	0.91

Abbreviations: FA: fractional abundance; ECOG PS: Eastern Cooperative Oncology Group performance status; CA 19-9: carbohydrate antigen 19-9; NLR: neutrophil-lymphocyte ratio; PLR: platelet-lymphocyte ratio.